Elcin Zan, MD, Chair, Division of Nuclear Medicine, Cleveland Clinic
Elcin Zan, MD is the Chair of Nuclear Medicine at Cleveland Clinic. Elcin focuses on exploring the full potential of Radiopharmaceutical Therapies in oncology to meaningfully improve patient outcomes in clinic and research. Elcin and her team develop AGI tools to study the collective intelligence of cancer from cells to body-wide networks integrating pathology and PET diagnostics.

Shaemus Gleason, Executive Vice President, Clarity Pharmaceuticals
Shaemus is an accomplished professional with over 16 years of experience in the radiopharmaceutical industry. His career has spanned various roles in both small biotech firms and large pharmaceutical companies, providing him with a comprehensive understanding of the field. Shaemus's expertise ranges from the manufacturing of radiopharmaceuticals to their development in clinical trials and subsequent commercial launch and execution. This diverse background has equipped him with the ability to adapt and excel in start-up environments and with evolving product offerings. Shaemus has spoke at a number of international conference on various subjects related to radiopharmaceuticals. He also sits in the board of the Council of Radiopharmaceutical Manufacturers and is a previous board member of NRMAP, the National Radionuclide Measurement Assurance Program.

Jeff Jones, PhD, Managing Director, Equity Research, Oppenheimer & Co., Inc.
Jeff Jones is a Managing Director and Senior Analyst covering Biotechnology at Oppenheimer. He covers ~20 small to mid-cap biopharma companies, principally in the oncology and I&I spaces, and leads Oppenheimer’s coverage of the targeted radiopharmaceutical space. Prior to joining Oppenheimer, Jeff Founded and ran One Health Advisors, LLC which provided strategic advisory services for the human and animal biopharma sector. Prior to founding One Health, Jeff served in a variety of roles within biotechnology companies, including Vice President of Business Development at Aratana Therapeutics and Chief Operating Officer at Pharmathene. Jeff received a B.A. in Biology from the University of Virginia, and a Ph.D. in Cell and Molecular Biology from Baylor College of Medicine. He also holds an MBA from Cornell University’s Johnson Graduate School of Management.

Matthew Roden, PhD, President & CEO, Aktis Oncology
Matthew Roden is President and Chief Executive Officer at Aktis Oncology, and a member of the Aktis Board of Directors. Matt is also an Executive Partner at MPM BioImpact and serves on the Boards of Directors of ORNA Therapeutics and a stealth NewCo. Matt’s career has spanned senior leadership roles in the biopharma industry, the healthcare equity capital markets, and in basic science as an immunologist and structural biologist. Prior to Aktis Oncology and MPM, Matt was a senior leader at Bristol Myers Squibb, serving as SVP and Head of Enterprise Strategy, as Head of Strategic Corporate Development, accountable for mergers and acquisitions, and as Head of Global BD Assessment, leading business development search and evaluation activities worldwide for all therapeutic categories. Matt served on the R&D Leadership Team representing External Innovation and led teams on business development transactions cumulatively valued at over $125 billion. Prior to his corporate leadership career, Matt was a leading equity research analyst covering the global biotechnology sector at UBS and J.P. Morgan. He holds a PhD from the Albert Einstein College of Medicine and was a pre-doctoral fellow at the National Cancer Institute. In his free time, Matt enjoys tackling home improvement projects and spending time with his family sailing or on the ski slopes.